Lorlatinib
Sign in to save this workspacePrimary targets: ALK · FDA status: FDA Approved
Selectivity scorecard
KISS
97.24
Gini
0.694
CATDS
0.018
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Lorlatinib. Strongest target: ROS_ROS1 at 99.5% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ROS_ROS1 | 99.5% | 0.5% |
| 2 | ACK1 | 99.3% | 0.7% |
| 3 | FER | 98.1% | 1.9% |
| 4 | FAK_PTK2 | 97.7% | 2.3% |
| 5 | PYK2 | 97.6% | 2.4% |
| 6 | ALK | 97.2% | 2.8% |
| 7 | TYK1_LTK | 93.8% | 6.2% |
| 8 | FES_FPS | 93.7% | 6.3% |
| 9 | GRK7 | 92.0% | 8.0% |
| 10 | TRKC | 91.3% | 8.7% |
| 11 | TRKB | 90.5% | 9.5% |
| 12 | PHKG2 | 88.5% | 11.5% |
| 13 | TNK1 | 87.9% | 12.1% |
| 14 | STK22D_TSSK1 | 86.4% | 13.6% |
| 15 | NEK8 | 81.2% | 18.8% |
| 16 | PLK4_SAK | 80.6% | 19.4% |
| 17 | FRK_PTK5 | 80.0% | 20.0% |
| 18 | CAMKK2 | 79.2% | 20.8% |
| 19 | DCAMKL1 | 77.5% | 22.5% |
| 20 | SLK_STK2 | 73.0% | 27.0% |
Selectivity landscape
Where Lorlatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Lorlatinib.
Atlas insights for Lorlatinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1038.34 | |
| ALLOGRAFT_REJECTION | 3752.33 | |
| ANDROGEN_RESPONSE | 1049.52 | |
| ANGIOGENESIS | 703.40 | |
| APICAL_JUNCTION | 3746.83 | |
| APICAL_SURFACE | 338.91 | |
| APOPTOSIS | 2847.01 | |
| BILE_ACID_METABOLISM | 338.15 | |
| CHOLESTEROL_HOMEOSTASIS | 479.91 | |
| COAGULATION | 487.61 | |
| COMPLEMENT | 2129.23 | |
| DNA_REPAIR | 681.21 | |
| E2F_TARGETS | 2137.26 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 840.15 | |
| ESTROGEN_RESPONSE_EARLY | 1532.39 | |
| ESTROGEN_RESPONSE_LATE | 1206.29 | |
| FATTY_ACID_METABOLISM | 261.45 | |
| G2M_CHECKPOINT | 1689.63 | |
| GLYCOLYSIS | 1481.40 | |
| HEDGEHOG_SIGNALING | 443.04 | |
| HEME_METABOLISM | 744.37 | |
| HYPOXIA | 1843.91 | |
| IL2_STAT5_SIGNALING | 1274.84 | |
| IL6_JAK_STAT3_SIGNALING | 2161.80 | |
| INFLAMMATORY_RESPONSE | 2264.27 | |
| INTERFERON_ALPHA_RESPONSE | 306.57 | |
| INTERFERON_GAMMA_RESPONSE | 2622.01 | |
| KRAS_SIGNALING_DN | 547.54 | |
| KRAS_SIGNALING_UP | 1382.39 | |
| MITOTIC_SPINDLE | 2429.67 | |
| MTORC1_SIGNALING | 1724.76 | |
| MYC_TARGETS_V1 | 1421.13 | |
| MYC_TARGETS_V2 | 463.05 | |
| MYOGENESIS | 1408.93 | |
| NOTCH_SIGNALING | 181.81 | |
| OXIDATIVE_PHOSPHORYLATION | 336.31 | |
| P53_PATHWAY | 1336.41 | |
| PANCREAS_BETA_CELLS | 111.07 | |
| PEROXISOME | 334.05 | |
| PI3K_AKT_MTOR_SIGNALING | 3646.44 | |
| PROTEIN_SECRETION | 924.55 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 128.32 | |
| SPERMATOGENESIS | 779.84 | |
| TGF_BETA_SIGNALING | 708.41 | |
| TNFA_SIGNALING_VIA_NFKB | 1725.03 | |
| UNFOLDED_PROTEIN_RESPONSE | 701.66 | |
| UV_RESPONSE_DN | 1767.05 | |
| UV_RESPONSE_UP | 1566.79 | |
| WNT_BETA_CATENIN_SIGNALING | 869.65 | |
| XENOBIOTIC_METABOLISM | 867.94 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.847 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.837 |
| SRR23303752 | — | 0.836 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.825 |
| C3N-03420 | — | 0.824 |
Annotations
Sign in to read and post annotations.
Loading…